The Scottish Medicines Consortium (SMC) has recommended that Kesimpta can be prescribed for people with relapsing remitting MS who are having relapses or have MRI evidence of MS activity.
This is excellent news! The approval of Kesimpta in Scotland increases the choices for people with relapsing MS. An expanding range of drugs, working in different ways and with different benefits and risks, means more people can find the treatment that is best for them. Kesimpta offers access to an effective treatment which doesn’t require regular hospital visits.
- David Martin, Chief Executive Officer, MS Trust
NICE recommended Kesimpta for the NHS in England and Wales earlier this year.
In Northern Ireland, the Department of Health reviews NICE guidance for NHS use.
Kesimpta is self-injected under the skin once a month.
In clinical trials for relapsing MS, Kesimpta reduced the risk of relapse by 50-59% compared to Aubagio, reduced disability progression and the number of lesions seen on MRI scans.
Kesimpta binds to a marker (CD20) on the surface of B cells, a type of white blood cell (lymphocyte) which is thought to be involved when the immune system attacks the myelin coating of nerves. Targeted B cells are destroyed. Kesimpta works in similar way to Ocrevus (ocrelizumab).
In clinical trials, the most frequent side effects were injection-related reactions. Most of these were mild to moderate, cleared up the same or following day and were associated with the first Kesimpta injection; they were less frequent with subsequent injections. Other side effects that occurred in at least 10% of those taking Kesimpta were head colds, headache, chest infections and urinary tract infections.
Stem cell transplants in the news
5 Jul 2021 - 00:00
Difficulties accessing NHS stem cell transplants (also known as HSCT or AHSCT) for multiple sclerosis were highlighted in national newspapers this weekend.
MS onset in childhood: do disease modifying drugs delay long term disability?
17 Jun 2021 - 00:00
Researchers have investigated how the risk of developing long term disability has changed over the last three decades for people whose MS begins in childhood.
Who gets MS and why?
17 May 2021 - 00:00
The number of people being diagnosed with multiple sclerosis around the world is increasing. In this article we take a look at recent research which investigates who might be more succeptible to multiple sclerosis and why that might be.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.